Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 144

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 144
---
     | 10-2022-7039076 |     | 11/6/2014 |     | 11/6/2015  |     |            |     |            |     | 11/6/2035  |     | Pending |     | University Of Pittsburgh of The Commonwealth System of Higher Education/ Carnegie Mellon University |
| Japan         |     | Microneedle arrays for cancer therapy applications |     |      2024189676 |     | 11/6/2014 |     | 11/6/2015  |     |            |     |            |     | 11/6/2035  |     | Pending |     | University Of Pittsburgh of The Commonwealth System of Higher Education/ Carnegie Mellon University |
| Singapore     |     | Microneedle arrays for cancer therapy applications |     |     1002004900T |     | 11/6/2014 |     | 11/6/2015  |     |            |     |            |     | 11/6/2035  |     | Pending |     | University Of Pittsburgh of The Commonwealth System of Higher Education/ Carnegie Mellon University |
| Korea         |     | Microneedle arrays for cancer therapy applications |     | 10-2024-7043044 |     | 11/6/2014 |     | 11/6/2015  |     |            |     |            |     | 11/6/2035  |     | Pending |     | University Of Pittsburgh of The Commonwealth System of Higher Education/ Carnegie Mellon University |

<div align='center'>97

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.PURSUANT TO 17 C.F.R. SECTION 200.83</div>

Teverelix

On August 29, 2025, we completed the acquisition of 98.6% of the issued and outstanding shares of Antev, a clinical stage biotech company developing Teverelix as a first-in-market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention episodes due to enlarged prostate.

Teverelix is a long-acting GnRH antagonist. Unlike GnRH agonists, which can cause a surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions.

Acute Urinary Retention Indication